Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV
Abstract Introduction The pharmacokinetics, drug–drug interaction potential, and safety of a new HIV-1 capsid inhibitor, VH4004280 (VH-280), are described in this first-time-in-human study. Methods This randomized, double-blind, placebo-controlled, phase 1 study assessed oral VH-280 in adults withou...
Saved in:
| Main Authors: | Nilay Thakkar, Rulan Griesel, Amy Pierce, Veronica Bainbridge, Bronagh Shepherd, Konstantinos Angelis, Andrew Tomlinson, Yash Gandhi, Darin Brimhall, Daijha Anderson, Susan Andrews, Carolina Acuipil, Cynthia McCoig, Mark Baker, Paul Benn |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01154-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV
by: Nilay Thakkar, et al.
Published: (2025-04-01) -
Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir
by: Lorenzo Briganti, et al.
Published: (2025-05-01) -
How HIV-1 Uses the Metabolite Inositol Hexakisphosphate to Build Its Capsid
by: Leo C. James
Published: (2025-05-01) -
Computational Approaches to Predict Hepatitis B Virus Capsid Protein Mutations That Confer Resistance to Capsid Assembly Modulators
by: Gideon Tolufashe, et al.
Published: (2025-02-01) -
Interplay between the cyclophilin homology domain of RANBP2 and MX2 regulates HIV-1 capsid dependencies on nucleoporins
by: Haley Flick, et al.
Published: (2025-03-01)